ACS Medicinal Chemistry Letters · 2011 · 91 citations · 11 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryMolecular OncologyComputational Drug DiscoveryLigand BindingLigand-based DesignMolecular DockingProtein-ligand DockingTyrosine Kinase InhibitorsAxl Receptor Tyrosine KinaseAxl SignalingHomologyHomology Model RefinementKinase Inhibitor Library DesignSmall Molecule Tyrosine Kinase InhibitorsStructure-based De Novo DesignStructure-based Ligand Design
The receptor tyrosine kinase AXL has emerged in recent years as an potential oncology target due to its over expression in several types of cancers coupled with its ability to promote tumor growth and metastasis. In order to identify small molecule inhibitors of AXL, we built a homology model of its catalytic domain to virtually screen and identify scaffolds displaying an affinity for AXL. Further computational and structure-based design resulted in the synthesis of a series of 2,4,5-trisubstitued pyrimidines which demonstrated potent inhibition of AXL in vitro (IC(50) 19 nM) and strongly inhibited the growth of several pancreatic cell lines.
11
Y Li, X Ye, Chalet Tan et al. · Oncogene · 2009 · 284 citations
Medicine, Cancer Biology, Oncology +14